Recently AbbVie closed its acquisition of Aliada Therapeutics ... And it announced that it will buy out Nimble Therapeutics, which has a pipeline of immunology candidates, for $200 million.
Hosted on MSN2mon
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish"The addition of Nimble's pipeline to AbbVie's existing pipeline ... Just last week, AbbVie finalized a $1.4 billion acquisition of Aliada Therapeutics, targeting an experimental Alzheimer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback